IDH2 and acute myeloid leukemia: Of interest, in a subset of patients in whom concurrent IDH1 mutation analysis and MRD-MFC assessment was performed, IDH1 or IDH2 clearance was observed in 60% and 90% of MRD-MFC negative patients, indicative of the molecular heterogeneity commonly observed in AML [65].